These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 33734912)
1. A novel approach for the treatment of hypertension with the soluble guanylate cyclase stimulating drug. Chrysant SG Expert Opin Drug Saf; 2021 Jun; 20(6):635-640. PubMed ID: 33734912 [TBL] [Abstract][Full Text] [Related]
2. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease. Boerrigter G; Burnett JC Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086 [TBL] [Abstract][Full Text] [Related]
3. The nitric oxide-soluble guanylate cyclase-cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase. Benza RL; Grünig E; Sandner P; Stasch JP; Simonneau G Eur Respir Rev; 2024 Jan; 33(171):. PubMed ID: 38508664 [TBL] [Abstract][Full Text] [Related]
4. Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of Disease. Tobin JV; Zimmer DP; Shea C; Germano P; Bernier SG; Liu G; Long K; Miyashiro J; Ranganath S; Jacobson S; Tang K; Im GJ; Sheppeck J; Moore JD; Sykes K; Wakefield J; Sarno R; Banijamali AR; Profy AT; Milne GT; Currie MG; Masferrer JL J Pharmacol Exp Ther; 2018 Jun; 365(3):664-675. PubMed ID: 29643251 [TBL] [Abstract][Full Text] [Related]
5. Tirofiban increases soluble guanylate cyclase in rat vascular walls: pharmacological and pathophysiological consequences. Ruiz-Torres MP; Griera M; Chamorro A; Díez-Marqués ML; Rodríguez-Puyol D; Rodríguez-Puyol M Cardiovasc Res; 2009 Apr; 82(1):125-32. PubMed ID: 19126601 [TBL] [Abstract][Full Text] [Related]
6. Soluble guanylate cyclase stimulators for the treatment of hypertension: Discovery of MK-2947. Brockunier L; Stelmach J; Guo J; Spencer T; Rosauer K; Bansal A; Cai SJ; Chen N; Cummings J; Huang L; Johnson T; Levesque S; Luo L; Maloney K; Metzger J; Mortko C; Ortega K; Pai LY; Pereira A; Salituro G; Shang J; Shepherd C; Sherrie Xu S; Yang Q; Cui J; Roy S; Parmee E; Raghavan S Bioorg Med Chem Lett; 2020 Nov; 30(21):127574. PubMed ID: 32980512 [TBL] [Abstract][Full Text] [Related]
7. Inhaled nitric oxide decreases pulmonary soluble guanylate cyclase protein levels in 1-month-old lambs. Thelitz S; Bekker JM; Ovadia B; Stuart RB; Johengen MJ; Black SM; Fineman JR J Thorac Cardiovasc Surg; 2004 May; 127(5):1285-92. PubMed ID: 15115984 [TBL] [Abstract][Full Text] [Related]
14. The nitric oxide/soluble cyclic guanylase/cyclic guanosine monophosphate pathway is involved in the cardiovascular effects of a novel α1- and β-adrenoceptor antagonist. Kubacka M; Mogilski S; Bednarski M; Raźny K; Sapa J; Waszkielewicz AM; Marona H; Filipek B Pharmacology; 2014; 94(5-6):287-95. PubMed ID: 25531925 [TBL] [Abstract][Full Text] [Related]
16. Soluble Guanylyl Cyclase Activators-Promising Therapeutic Option in the Pharmacotherapy of Heart Failure and Pulmonary Hypertension. Grześk G; Witczyńska A; Węglarz M; Wołowiec Ł; Nowaczyk J; Grześk E; Nowaczyk A Molecules; 2023 Jan; 28(2):. PubMed ID: 36677920 [TBL] [Abstract][Full Text] [Related]
17. Vasorelaxing and antihypertensive effects of 7,8-dihydroxyflavone. Huai R; Han X; Wang B; Li C; Niu Y; Li R; Qu Z Am J Hypertens; 2014 May; 27(5):750-60. PubMed ID: 24317273 [TBL] [Abstract][Full Text] [Related]
18. Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence. Sandner P; Stasch JP Respir Med; 2017 Jan; 122 Suppl 1():S1-S9. PubMed ID: 28341058 [TBL] [Abstract][Full Text] [Related]
19. New insights into the role of soluble guanylate cyclase in blood pressure regulation. Buys E; Sips P Curr Opin Nephrol Hypertens; 2014 Mar; 23(2):135-42. PubMed ID: 24419369 [TBL] [Abstract][Full Text] [Related]